抗MDA5阳性皮肌炎相关快速进展型间质性肺病的治疗推荐
该研究旨在制定抗黑色素瘤分化相关基因5(MDA5)阳性皮肌炎相关快速进展型间质性肺病(RPILD)的循证治疗推荐。工作组由风湿科、重症医学科、呼吸科、免疫科和内科专家组成,分两阶段确定关键领域并基于截至2018年4月的系统检索证据制定推荐。共134项研究符合纳入标准,构成免疫抑制治疗及辅助治疗的证据基础。总体共识为初始采用联合免疫抑制治疗,首选大剂量糖皮质激素联合钙调神经磷酸酶拮抗剂(联合或不联合环磷酰胺);钙调神经磷酸酶拮抗剂禁忌或治疗失败时可个体化切换或添加其他免疫抑制剂;血浆置换、多粘菌素B血液灌流和/或静脉免疫球蛋白可作为挽救选项;危及生命时可考虑ECMO作为等待临床反应或肺移植的桥接。最终形成13条推荐。
要点
- 抗MDA5阳性皮肌炎相关RPILD初始治疗首选大剂量糖皮质激素联合钙调神经磷酸酶拮抗剂(联合或不联合环磷酰胺)。
- 钙调神经磷酸酶拮抗剂禁忌或治疗失败时,可个体化切换或添加其他免疫抑制剂。
- 血浆置换、多粘菌素B血液灌流和/或静脉免疫球蛋白可作为挽救治疗选项。
- 危及生命的情况下应考虑ECMO,作为等待临床反应或肺移植的桥接。
- 共134项研究构成证据基础,形成13条推荐,总体共识为初始联合免疫抑制治疗。
适用人群与场景
- 抗MDA5阳性皮肌炎相关快速进展型间质性肺病(RPILD)患者。
处置流程与药物剂量
- 初始治疗首选大剂量糖皮质激素联合钙调神经磷酸酶拮抗剂,联合或不联合环磷酰胺。
- 钙调神经磷酸酶拮抗剂禁忌或治疗失败时,可个体化切换或添加其他免疫抑制剂。
- 血浆置换、多粘菌素B血液灌流和/或静脉免疫球蛋白可作为挽救治疗选项。
- 危及生命的情况下应考虑ECMO,作为等待临床反应或肺移植的桥接。
研究设计与关键结果
- 工作组由风湿科、重症医学科、呼吸科、免疫科和内科专家组成,分两阶段确定关键领域并基于截至2018年4月的系统检索证据制定推荐。
- 共134项研究符合纳入标准,构成免疫抑制治疗及辅助治疗的证据基础。
- 总体共识为初始采用联合免疫抑制治疗。
- 形成13条关于抗MDA5阳性皮肌炎相关RPILD治疗的推荐。
证据类型、等级与局限
- 证据类型:指南/共识,基于系统检索的134项研究及专家意见。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于抗MDA5阳性皮肌炎相关RPILD患者,初始治疗可采用大剂量糖皮质激素联合钙调神经磷酸酶拮抗剂(联合或不联合环磷酰胺)。
- 当钙调神经磷酸酶拮抗剂禁忌或治疗失败时,可个体化切换或添加其他免疫抑制剂。
- 血浆置换、多粘菌素B血液灌流和/或静脉免疫球蛋白可作为挽救治疗选项。
- 危及生命时可考虑ECMO作为等待临床反应或肺移植的桥接。
指南或共识出处
- Semin Arthritis Rheum 发布的抗MDA5阳性皮肌炎相关RPILD治疗推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The study aimed to develop evidence-based recommendations for the treatment of rapidly progressive interstitial lung disease (RPILD) associated with the anti-Melanoma Differentiation-Associated Gene 5-positive dermatomyositis (DM) syndrome.
METHODS: The task force comprised an expert panel of specialists in rheumatology, intensive care medicine, pulmonology, immunology, and internal medicine. The study was carried out in two phases: identifying key areas in the management of DM-RPILD syndrome and developing a set of recommendations based on a review of the available scientific evidence. Four specific questions focused on different treatment options were identified. Relevant publications in English, Spanish or French up to April 2018 were searched systematically for each topic using PubMed (MEDLINE), EMBASE, and Cochrane Library (Wiley Online). The experts used evidence obtained from these studies to develop recommendations.
RESULTS: A total of 134 studies met eligibility criteria and formed the evidentiary basis for the recommendations regarding immunosuppressive therapy and complementary treatments. Overall, there was general agreement on the initial use of combined immunosuppressive therapy. Combination of high-dose glucocorticoids and calcineurin antagonists with or without cyclophosphamide is the first choice. In the case of calcineurin antagonist contraindication or treatment failure, switching or adding other immunosuppressants may be individualized. Plasmapheresis, polymyxin B hemoperfusion and/or intravenous immunoglobulins may be used as rescue options. ECMO should be considered in life-threatening situations while waiting for a clinical response or as a bridge to lung transplant.
CONCLUSIONS: Thirteen recommendations regarding the treatment of the anti-MDA5 positive DM-RPILD were developed using research-based evidence and expert opinion.
参考来源
- Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020. PMID: 32534273. doi:10.1016/j.semarthrit.2020.03.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。